Scientists have developed inhalable lung cancer therapeutics utilizing mucoadhesive proteinic nanoparticles.

Boost productivity with these essential Microsoft Outlook tips. Learn how to organize your inbox, automate tasks, and ...

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Lung cancer remains one of the deadliest cancers globally. Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, is particularly challenging to treat due to difficulties ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

About Light Horse Therapeutics Light Horse Therapeutics emerged from the ... systematically interrogates complex signaling pathways in their native, cellular context to uncover unique sites of ...

Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...

Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...